Holen Sie sich die Stockscreener-App
256.10
1.07%
2.72
Handel nachbörslich:
256.11
0.010
+0.00%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ABBV?
Forum
Prognose
Dividendenhistorie
Schlusskurs vom Vortag:
$253.38
Offen:
$253.7
24-Stunden-Volumen:
4.47M
Relative Volume:
0.65
Marktkapitalisierung:
$452.48B
Einnahmen:
$62.82B
Nettoeinkommen (Verlust:
$3.60B
KGV:
126.32
EPS:
2.0274
Netto-Cashflow:
$19.98B
1W Leistung:
+4.62%
1M Leistung:
+18.30%
6M Leistung:
+18.48%
1J Leistung:
+38.54%
1-Tages-Spanne:
$252.60
$257.06
1-Wochen-Bereich:
$243.07
$260.96
52-Wochen-Spanne:
$184.90
$261.63
Abbvie Inc Stock (ABBV) Company Profile
Firmenname
Abbvie Inc
Sektor
Telefon
(847) 932-7900
Adresse
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Compare ABBV vs LLY, JNJ, MRK, NVS
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
256.10 | 447.67B | 62.82B | 3.60B | 19.98B | 2.0274 |
LLY
Lilly Eli Co
|
1,175.41 | 1.02T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
250.61 | 598.96B | 97.93B | 21.04B | 17.80B | 8.6278 |
MRK
Merck Co Inc
|
126.26 | 307.25B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
153.87 | 285.37B | 54.66B | 13.58B | 16.05B | 7.0171 |
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-30 | Hochstufung | BofA Securities | Neutral → Buy |
| 2026-04-21 | Eingeleitet | Canaccord Genuity | Buy |
| 2026-02-25 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2026-02-20 | Eingeleitet | Barclays | Overweight |
| 2026-01-08 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2026-01-07 | Fortgesetzt | UBS | Neutral |
| 2025-12-10 | Hochstufung | HSBC Securities | Hold → Buy |
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-11-04 | Herabstufung | DZ Bank | Buy → Hold |
| 2025-10-14 | Herabstufung | Erste Group | Buy → Hold |
| 2025-10-01 | Herabstufung | HSBC Securities | Buy → Hold |
| 2025-09-17 | Hochstufung | Berenberg | Hold → Buy |
| 2025-08-12 | Fortgesetzt | Piper Sandler | Overweight |
| 2025-08-07 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2025-05-14 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-04-22 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-12-10 | Fortgesetzt | BofA Securities | Neutral |
| 2024-12-05 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2024-11-22 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-11-04 | Hochstufung | Argus | Hold → Buy |
| 2024-10-17 | Eingeleitet | Bernstein | Mkt Perform |
| 2024-06-05 | Hochstufung | HSBC Securities | Hold → Buy |
| 2024-05-17 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-01-29 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2023-12-18 | Herabstufung | HSBC Securities | Buy → Hold |
| 2023-12-11 | Hochstufung | Goldman | Neutral → Buy |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-10-30 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2023-10-20 | Fortgesetzt | UBS | Neutral |
| 2023-09-29 | Eingeleitet | Raymond James | Outperform |
| 2023-07-25 | Eingeleitet | William Blair | Mkt Perform |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-04-05 | Herabstufung | Argus | Buy → Hold |
| 2023-03-01 | Eingeleitet | Guggenheim | Buy |
| 2023-02-22 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2023-02-10 | Hochstufung | SVB Securities | Underperform → Market Perform |
| 2022-11-18 | Eingeleitet | Credit Suisse | Outperform |
| 2022-11-08 | Herabstufung | Societe Generale | Buy → Hold |
| 2022-08-01 | Herabstufung | Atlantic Equities | Overweight → Neutral |
| 2022-05-23 | Eingeleitet | SVB Leerink | Underperform |
| 2022-05-06 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Overweight |
| 2022-02-28 | Herabstufung | UBS | Buy → Neutral |
| 2022-02-03 | Bestätigt | BMO Capital Markets | Outperform |
| 2022-02-03 | Bestätigt | Barclays | Equal Weight |
| 2022-02-03 | Bestätigt | BofA Securities | Neutral |
| 2022-02-03 | Bestätigt | Goldman | Neutral |
| 2022-01-13 | Eingeleitet | Redburn | Buy |
| 2022-01-12 | Bestätigt | BMO Capital Markets | Outperform |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Overweight |
| 2021-11-23 | Hochstufung | Societe Generale | Hold → Buy |
| 2021-07-27 | Fortgesetzt | Truist | Buy |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Outperform |
| 2020-11-10 | Fortgesetzt | Bernstein | Outperform |
| 2020-09-29 | Eingeleitet | Berenberg | Hold |
| 2020-06-23 | Hochstufung | Atlantic Equities | Neutral → Overweight |
| 2020-06-09 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2020-06-02 | Hochstufung | Argus | Hold → Buy |
| 2020-05-18 | Fortgesetzt | BofA/Merrill | Neutral |
| 2020-05-12 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2020-05-11 | Fortgesetzt | Morgan Stanley | Overweight |
| 2020-04-20 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-03-23 | Herabstufung | Societe Generale | Buy → Hold |
| 2020-02-27 | Eingeleitet | Barclays | Equal Weight |
| 2020-02-06 | Eingeleitet | Mizuho | Buy |
| 2020-01-07 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2019-12-26 | Bestätigt | Cowen | Outperform |
| 2019-09-26 | Hochstufung | Citigroup | Neutral → Buy |
| 2019-08-20 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2019-06-27 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2019-06-26 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2019-05-28 | Eingeleitet | Goldman | Neutral |
| 2019-04-29 | Hochstufung | BMO Capital Markets | Underperform → Market Perform |
Alle ansehen
Abbvie Inc Aktie (ABBV) Neueste Nachrichten
How Investors May Respond To AbbVie (ABBV) Securing EU Approval For Short-Acting Boey Aesthetic Toxin - Yahoo Finance
3 Reasons to Buy AbbVie Stock Like There's No Tomorrow - The Motley Fool
EBIT per share of AbbVie, Inc. – BCS:ABBVCL1 - TradingView
3 Reasons to Buy AbbVie Stock Like There's No Tomorrow - The Motley Fool
AbbVie (ABBV) Beats Stock Market Upswing: What Investors Need to Know - Yahoo Finance
AbbVie Inc. stock outperforms competitors on strong trading day - MarketWatch
Enterprise value of AbbVie, Inc. – BCS:ABBV0 - TradingView
AbbVie Stock Zigs When The Market Zags - Trefis
AbbVie stock advances on a strong 2025 base - Ad-hoc-news.de
J&J, Eli Lilly, or AbbVie? How to Play Big Pharma in a Diverging Market - finance.biggo.com
AbbVie’s Allergan gets European nod for its Botox-lite treatment - Crain's Chicago Business
A 54-Year Dividend Streak Meets a $10.9 Billion Acquisition: Here’s Why AbbVie’s Payouts Are Safe - NAI500
AbbVie stock holds firm as Humira biosimilar impact is offset by Skyrizi and Rinvoq growth - ad-hoc-news.de
How Will AbbVie's $10.9 Billion Acquisition of Apogee Impact Its Dividend? - The Motley Fool
AbbVie stock trades steady as Skyrizi and Rinvoq drive double digit revenue growth - ad-hoc-news.de
AbbVie stock trades steady as investors focus on Skyrizi and Rinvoq growth after mixed quarter - ad-hoc-news.de
AbbVie (ABBV) Wins EU Approval For Boey Frown Line Treatment In Europe - Yahoo Finance UK
AbbVie granted EU nod for Boey anti-wrinkle therapy (ABBV:NYSE) - Seeking Alpha
AbbVie stock holds gains as investors weigh Skyrizi and Rinvoq growth - ad-hoc-news.de
Is AbbVie Inc (ABBV) Overvalued After 4.2% Rally? GF Value Says - GuruFocus
Analysts Are Bullish on Top Healthcare Stocks: Fractyl Health, Inc. (GUTS), AbbVie (ABBV) - The Globe and Mail
AbbVie stock trades steadily as investors weigh Humira erosion and pipeline progress - ad-hoc-news.de
Will AbbVie's Neuroscience Franchise Deliver Another Strong Quarter? - TradingView
Is AbbVie (NYSE:ABBV) Fully Valued After Tepkinly? - Kalkine Media
Why AbbVie (ABBV) Stock Is Up Today - Quiver Quantitative
AbbVie Inc Stock (ABBV) Moved Up by 3.32% on Jul 16: What Signal Does It Send? - TradingKey
Is AbbVie (ABBV) Fully Priced Despite Tepkinly Approval And Cash Flow? - simplywall.st
AHA urges court to reject AbbVie bid to change 340B program rules - EIN News
AbbVie stock holds steady as its diversified portfolio underpins long-term growth - ad-hoc-news.de
ABBV Maintained by Citigroup -- Price Target Raised to $260 - GuruFocus
Should You Buy, Sell or Hold ABBV Stock After Its 9% YTD Rise? - TradingView
AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
AbbVie vs Baxter: One Golden Cross Is Real, One Is a Trap - Yahoo Finance
Nxera Pharma Webinar for Financial Results Presentation - GlobeNewswire Inc.
Red day on Tuesday for AbbVie stock after losing 1.31% - StockInvest.us
AbbVie (ABBV) Stock Looks Fully Priced After A 152% Run - Yahoo Finance
AbbVie Tokenized Stock price today, ABBVX to USD chart, marketcap and volume - CryptoSlate
AbbVie Inc. stock outperforms competitors despite losses on the day - MarketWatch
AbbVie (ABBV) Faces Seventh Consecutive Loss Amid Mixed Sentimen - GuruFocus
AbbVie extends slide to a seventh straight session - MSN
AbbVie price seeks a supportive bottomForecast today14-07-2026 - Economies.com
Is AbbVie (ABBV) a Buy as Wall Street Analysts Look Optimistic? - Yahoo! Finance Canada
SkinMedica® Deepens Commitment to Regenerative Science with Continued Investment in Research and Development - Investing News Network
AbbVie stock: Is ABBV outperforming the healthcare sector? - MSN
Donald Trump's Drug-Pricing Deals Are Reshaping Big Pharma -- Here's What That Means for Pfizer, AbbVie, and Bristol Myers Squibb - The Globe and Mail
AbbVie pharmaceutical project moves forward in Durham: 'Huge deal' - ABC11 News
Apogee Therapeutics (NASDAQ: APGE) backs AbbVie’s $135.11‑per‑share all‑cash deal - Stock Titan
ABBV Maintained by UBS -- Price Target Raised to $260 - GuruFocus
BMO Capital Adjusts Price Target on AbbVie to $300 From $258, Maintains Outperform Rating - marketscreener.com
ABBV Maintained by BMO Capital -- Price Target Raised to $300 - GuruFocus
UBS Adjusts Price Target on AbbVie to $260 From $230, Maintains Neutral Rating - marketscreener.com
Finanzdaten der Abbvie Inc-Aktie (ABBV)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.50%
0.46%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):